Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Nüsslein H[au]:

Search results

Items: 1 to 50 of 67

1.

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.

Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüßlein H, Navarro F, Elbez Y, Chartier M, Hackl R, Rauch C, Connolly SE.

Wien Med Wochenschr. 2019 Oct 25. doi: 10.1007/s10354-019-00710-8. [Epub ahead of print]

PMID:
31654156
2.

Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.

Alten R, Feist E, Lorenz HM, Nüßlein H, Voll RE, Chartier M, Elbez Y, Rauch C.

Clin Rheumatol. 2019 Nov;38(11):3049-3059. doi: 10.1007/s10067-019-04648-5. Epub 2019 Jul 12.

PMID:
31300979
3.

Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

Alten R, Mariette X, Lorenz HM, Nüßlein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M.

Clin Rheumatol. 2019 May;38(5):1535. doi: 10.1007/s10067-019-04545-x.

PMID:
30972577
4.

Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.

Burmester G, Nüsslein H, von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, Lendl U, Fricke D, Müller-Ladner U.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):842-851. Epub 2019 Mar 7.

PMID:
30873942
5.

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

Alten R, Mariette X, Lorenz HM, Nüßlein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M.

Clin Rheumatol. 2019 May;38(5):1413-1424. doi: 10.1007/s10067-019-04449-w. Epub 2019 Feb 21. Erratum in: Clin Rheumatol. 2019 Apr 11;:.

PMID:
30790095
6.

[Cardiovascular comorbidities in rheumatoid arthritis].

Krüger K, Nüßlein H.

Z Rheumatol. 2019 Apr;78(3):221-227. doi: 10.1007/s00393-018-0584-5. Review. German.

PMID:
30656399
7.

Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.

Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J.

J Rheumatol. 2019 May;46(5):460-466. doi: 10.3899/jrheum.180028. Epub 2018 Dec 1.

PMID:
30504510
8.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K.

Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Review. German.

PMID:
29968101
9.

Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.

Galeazzi M, Alten R, Chartier M, Elbez Y, Fusaro E, Le Bars M, Lorenz HM, Pagano Mariano G, Muratore M, Nüßlein HG, Patanè G.

Clin Exp Rheumatol. 2018 Sep-Oct;36(5):935-936. Epub 2018 Mar 21. No abstract available.

10.

Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nüßlein HG, Chartier M, Elbez Y, Rauch C, Le Bars M.

RMD Open. 2017 Dec 29;3(2):e000538. doi: 10.1136/rmdopen-2017-000538. eCollection 2017.

11.

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.

Alten R, Nüßlein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.

RMD Open. 2017 Feb 13;3(1):e000345. doi: 10.1136/rmdopen-2016-000345. eCollection 2017.

12.

[Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF].

Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüsslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche AK, Braun J.

Z Rheumatol. 2017 Mar;76(2):118-124. doi: 10.1007/s00393-016-0249-1. Review. German.

PMID:
28078432
13.

The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.

Mariette X, Alten R, Nüßlein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.

Joint Bone Spine. 2017 Oct;84(5):571-576. doi: 10.1016/j.jbspin.2016.10.011. Epub 2016 Dec 30.

14.

[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüßlein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche A, Braun J.

Z Rheumatol. 2016 Aug;75 Suppl 2:11-60. doi: 10.1007/s00393-016-0147-6. Review. German. No abstract available.

PMID:
27481119
15.

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M.

Clin Exp Rheumatol. 2016 May-Jun;34(3):489-99. Epub 2016 Mar 10.

PMID:
26966919
16.

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.

Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, Le Bars M.

RMD Open. 2016 Feb 15;2(1):e000228. doi: 10.1136/rmdopen-2015-000228. eCollection 2016.

17.

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Le Bars M.

BMC Musculoskelet Disord. 2015 Jul 30;16:176. doi: 10.1186/s12891-015-0636-9.

18.

Gustatory and olfactory function in patients with granulomatosis with polyangiitis (Wegener's).

Proft F, Steinbach S, Dechant C, Witt M, Reindl C, Schulz S, Vielhauer V, Hilge R, Laubender RP, Manger K, Nüsslein H, Wendler J, Schuch F, Schulze-Koops H, Grunke M.

Scand J Rheumatol. 2014;43(6):512-8. doi: 10.3109/03009742.2014.915056. Epub 2014 Sep 10.

PMID:
25204208
19.

[Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].

Tarner IH, Albrecht K, Fleck M, Gromnica-Ihle E, Keyßer G, Köhler L, Kötter I, Krüger K, Kuipers J, Nüßlein H, Rubbert-Roth A, Wollenhaupt J, Schneider M, Manger B, Müller-Ladner U; internationalen 3e-Initiative.

Z Rheumatol. 2014 May;73(4):363-73. doi: 10.1007/s00393-013-1249-z. German.

PMID:
24590079
20.

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Bars ML.

BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14.

21.

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; German Society of Rheumatology.

Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Review.

PMID:
23942828
22.

[Pain treatment with traditional NSAR and coxibs: an interdisciplinary assessment].

Fischbach W, Baerwald C, Darius H, Gross M, Nickenig G, Nüßlein H, Stichtenoth DO.

Dtsch Med Wochenschr. 2013 Jan;138(3):91-6. doi: 10.1055/s-0032-1327397. Epub 2013 Jan 8. Review. German. No abstract available.

PMID:
23299345
23.

[How early would we really administer biologics?].

Nüßlein HG.

Z Rheumatol. 2012 Dec;71(10):838-9. doi: 10.1007/s00393-012-1072-y. German. Erratum in: Z Rheumatol. 2013 Feb;72(1):19.

PMID:
23202994
24.

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Krüger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; European League of Associations for Rheumatology (EULAR).

Z Rheumatol. 2012 Sep;71(7):592-603. doi: 10.1007/s00393-012-1038-0. German.

PMID:
22930110
25.

Risk of infections in rheumatoid arthritis patients treated with tocilizumab.

Lang VR, Englbrecht M, Rech J, Nüsslein H, Manger K, Schuch F, Tony HP, Fleck M, Manger B, Schett G, Zwerina J.

Rheumatology (Oxford). 2012 May;51(5):852-7. doi: 10.1093/rheumatology/ker223. Epub 2011 Aug 24.

PMID:
21865281
26.

Rare monogenetic syndromes in rheumatology practice.

Manger K, Nüsslein H, Schett G, Manger B.

Clin Rheumatol. 2009 Jun;28(6):623-30. doi: 10.1007/s10067-009-1117-z. Epub 2009 Feb 18. Review.

PMID:
19224127
27.

Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial.

Kalden JR, Nüsslein HG, Wollenhaupt J, Burmester GR, Krüger K, Antoni C.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5):834-40.

PMID:
19032816
28.

[Current therapeutic strategy for rheumatoid arthritis].

Wollenhaupt J, Alten R, Burkhardt H, Edelmann E, Gromnica-Ihle E, Krause A, Krüger K, Manger B, Lorenz H, Müller-Ladner U, Nüsslein H, Pott HG, Tony H, Schneider M.

MMW Fortschr Med. 2006 Oct 19;148(42):38-42; quiz 43. German.

PMID:
17621798
29.

[Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Manger B, Michels H, Nüsslein HG, Schneider M, Sieper J; Kommission Pharmakotherapie der DGRh.

Z Rheumatol. 2007 Feb;66(1):72-5. German.

PMID:
17221253
30.

[Rheumatoid arthritis at the cervical spine -- an underestimated problem].

Schwarz-Eywill M, Friedberg R, Stösslein F, Unger L, Nüsslein H.

Dtsch Med Wochenschr. 2005 Aug 19;130(33):1866-70. German.

PMID:
16118728
31.

[Glucocorticoid therapy in collagen diseases diseases].

Unger L, Kayser M, Enderlein M, Manger K, Nüsslein H.

Z Rheumatol. 2005 Apr;64(3):162-9. Review. German.

PMID:
15868333
32.

Interstitial granulomatous dermatitis with plaques and arthritis.

Wollina U, Schönlebe J, Unger L, Weigel K, Köstler E, Nüsslein H.

Clin Rheumatol. 2003 Oct;22(4-5):347-9.

PMID:
14579165
33.

Successful treatment of severe rheumatoid vasculitis by infliximab.

Unger L, Kayser M, Nüsslein HG.

Ann Rheum Dis. 2003 Jun;62(6):587-8. No abstract available.

34.

[Acute renal failure as a sequela of mushroom poisoning with Cortinarius speciocissimus].

Münstermann S, Heinicke HJ, Kayser M, Nüsslein H.

Med Klin (Munich). 2002 Feb 15;97(2):96-8. German.

PMID:
11910876
35.

[Rare manifestation of large vessel vasculitis in systemic lupus erythematosus].

Schwarz-Eywill M, Rinaldi N, Barth T, Nüsslein HG.

Z Rheumatol. 2000 Oct;59(5):330-3. German.

PMID:
11142928
36.

Seltene Manifestation einer Grossgefassvaskulitis bei|| systemischem Lupus erythematodes.

Schwarz-Eywill M, Rinaldi N, Barth T, Nusslein HG.

Z Rheumatol. 2000 Oct;59(5):330-3. German.

PMID:
11116804
37.

[Relevance of a standardized staging study in patients with systemic vasculitis].

Schwarz-Eywill M, Weiss A, Unger L, Nüsslein H.

Z Rheumatol. 2000 Jun;59(3):183-90. German.

PMID:
10929447
38.

In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.

Lorenz HM, Grünke M, Hieronymus T, Antoni C, Nüsslein H, Schaible TF, Manger B, Kalden JR.

J Rheumatol. 2000 Feb;27(2):304-10.

PMID:
10685789
39.

[Transplantation immunology].

Nüsslein H, Geidel H.

Z Arztl Fortbild Qualitatssich. 1999 Mar;93(2):83. German. No abstract available.

PMID:
10355055
40.

[Christian Georg Schmorl].

Nüsslein H, Justus J.

Z Rheumatol. 1999 Feb;58(1):1. German. No abstract available.

PMID:
10198982
41.

First-time manifestation of generalized Wegener's granulomatosis despite methotrexate.

Schwarz-Eywill M, Mantaka P, Unger L, Wittek A, Nüsslein H.

Br J Rheumatol. 1998 Mar;37(3):344-5. No abstract available.

PMID:
9566683
42.

[Arthralgia, sudden drop in sedimentation rate and hour-glass nails].

Manger B, Nüsslein H.

Med Klin (Munich). 1997 Oct 15;92(10):604. German. No abstract available.

PMID:
9446008
43.

Increase of intracellular calcium is the essential signal for the expression of CD40 ligand.

Nüsslein HG, Frosch KH, Woith W, Lane P, Kalden JR, Manger B.

Eur J Immunol. 1996 Apr;26(4):846-50.

PMID:
8625977
44.

In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.

Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, Nüsslein H, Woody J, Kalden JR, Manger B.

J Immunol. 1996 Feb 15;156(4):1646-53.

PMID:
8568271
45.

Origin and immunoregulation of autoantibodies against intestinal alkaline phosphatase.

Kolbus N, Beuche W, Schlaf G, Nüsslein HG, Felgenhauer K, Mäder M.

Scand J Immunol. 1995 Apr;41(4):414-20.

PMID:
7899830
46.

Anticardiolipin antibodies in HIV infection: association with cerebral perfusion defects as detected by 99mTc-HMPAO SPECT.

Rubbert A, Bock E, Schwab J, Marienhagen J, Nüsslein H, Wolf F, Kalden JR.

Clin Exp Immunol. 1994 Dec;98(3):361-8.

47.

In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion.

Klebl FH, Weber G, Kalden JR, Nüsslein HG.

Clin Exp Allergy. 1994 Nov;24(11):1022-9.

PMID:
7874601
48.
49.

Chronic lymphocytic leukemia cells induce non-T cells to produce IgE in the presence of interleukin-4.

Nüsslein HG, Dietz A, Burger R, Träg T, Kalden JR, Gramatzki M.

J Clin Immunol. 1993 Nov;13(6):397-405.

PMID:
8288724
50.

The role of T cells and the effect of hydrocortisone on interleukin-4-induced IgE synthesis by non-T cells.

Nüsslein HG, Träg T, Winter M, Dietz A, Kalden JR.

Clin Exp Immunol. 1992 Nov;90(2):286-92.

Supplemental Content

Loading ...
Support Center